why choose us

First received: October 09, 2023

Clinical Trial: Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hematologic Malignancy

Study Type: INTERVENTIONAL


Official Title: A Randomized, Open-Label, Multicenter, Phase 2a Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplanta

Brief Summary: This is a Phase 2a, open-label, multicenter study to evaluate the safety and efficacy of HMO (PBCLN-010) and B. infantis (PBCLN-014) on the gut microbiome and GI domination by pathobionts in participants receiving allo-HCT.Approximately 60 participants will be enrolled in this study, and all participants will undergo screening assessments up to 28 days before the first study drug dose (D 7).Participants meeting all the eligibility criteria based on the screening assessments will be enrolled and randomly assigned…

Read more